ABSTRACT
A series of bicyclic pyrazole carboxamides was synthesized and tested for inhibitory activity against the class III deacetylase sirtuin enzymes. Moderate to low micromolar inhibitory activities were obtained against SIRT1 and SIRT2. These bicyclic pyrazole compounds represent a new class of sirtuin inhibitors with a preference for SIRT1 over SIRT2.
Subject(s)
Bridged Bicyclo Compounds/chemistry , Pyrazoles/chemistry , Sirtuin 1/antagonists & inhibitors , Sirtuin 2/antagonists & inhibitors , Binding Sites , Catalytic Domain , Crystallography, X-Ray , Drug Evaluation, Preclinical , Molecular Dynamics Simulation , Protein Binding , Pyrazoles/chemical synthesis , Pyrazoles/metabolism , Sirtuin 1/metabolism , Sirtuin 2/metabolism , Structure-Activity RelationshipABSTRACT
In an effort to identify HDAC isoform selective inhibitors, we designed and synthesized novel, chiral 3,4-dihydroquinoxalin-2(1H)-one and piperazine-2,5-dione aryl hydroxamates showing selectivity (up to 40-fold) for human HDAC6 over other class I/IIa HDACs. The observed selectivity and potency (IC(50) values 10-200 nM against HDAC6) is markedly dependent on the absolute configuration of the chiral moiety, and suggests new possibilities for use of chiral compounds in selective HDAC isoform inhibition.
Subject(s)
Enzyme Inhibitors/chemistry , Histone Deacetylase Inhibitors , Histone Deacetylases/chemistry , Acetylation , Catalytic Domain , Chemistry, Pharmaceutical/methods , Drug Design , Histone Deacetylase 6 , Histone Deacetylases/metabolism , Histones/chemistry , Humans , Hydroxamic Acids/pharmacology , Inhibitory Concentration 50 , Models, Chemical , Piperazine , Piperazines/chemistry , Protein Isoforms , Tubulin/chemistryABSTRACT
The enhancer region in the human immunodeficiency virus type 1 (HIV-1) 5'-long terminal repeat (LTR) is very important for viral transcription. This promoter sequence binds both nuclear factor-kappaB and NFAT, two important modulators of HIV-1 gene expression. Previous studies have indicated that the enhancer regions of the different HIV-1 clade LTRs differ in their number of NF-kappaB-binding sites. In this study, we have compared the activation potential of the different HIV-1 clade and HIV-2 LTRs and assessed their interaction with NFAT and NF-kappaB. In T-cell lines and primary CD4(+) T-cells, the results showed that the HIV-1 clade E LTR (with a single NF-kappaB-binding site) was the weakest LTR regardless of the tested activators, whereas the HIV-2 LTR was the most responsive LTR. The clade E enhancer region was also demonstrated to be the weakest enhancer region in transfection experiments with luciferase reporter-based vectors. Electrophoretic mobility shift assays with extracts from activated CD4(+) T-cells indicated that, although NF-kappaB and NFAT bound all enhancers, HIV-1 clade E and HIV-2 LTR enhancers were poor binding targets for these two factors. Weak NFAT binding to clade E enhancers was also confirmed using NFAT1-expressing 293T cells in competition experiments. We have also shown the absence of interaction of NF-kappaB or NFAT with the third NF-kappaB repeat present in clade C. However, the clade C enhancer bound NFAT more efficiently than all other enhancer regions tested. Our results hence demonstrate for the first time that differences in the binding of NF-kappaB and NFAT to the enhancer regions could be responsible for some of the observed variation in HIV-1 clade LTR activation, whereas HIV-2 LTR activation seems mostly independent of these interactions.
